natgillin/translations-raw huggingface dataset:
Method according to any one of the preceding embodiments, wherein photocatalytic nanoparticles have primary particle size of less than 50 nm, preferably less than 30 nm, more preferably less than 20 nm, most preferably less than 10 nm. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da fotokatalitičke nanočestice imaju primarnu veličinu čestica manju od 50 nm, poželjno manju od 30 nm, poželjnije manje od 20 nm, a najpoželjnije manje od 10 nm.
A method according to claim 1, wherein said adsorption temperature is close to a temperature of sliding the reticular planes of the transition metal (19), in particular a temperature set between the temperature corresponding to absorption peaks a and B. 
Metoda prema zahtjevu 1, naznačena time da je navedena adsorpcijska temperatura blizu temperature pomicanja mrežastih ravnina prijelaznog metala (19), naročito temperature između temperature koja odgovara apsorpcijskim vršnim vrijednostima a 1 f3.
The method for installation and laying of a waterproof liner according to claim 1, characterised by providing a watertight connection device (44; 45) between flexible flaps (26) of adjoining waterproof panels (14), wherein each waterproof panel (14) consists of a single waterproof membrane in geosynthetic material. 
Postupak ugradnje i polaganja vodonepropusne obloge u skladu s patentnim zahtjevom 1, naznačen time, da se postavlja vodonepropusni spojni uređaj (44; 45) između savitljivih preklopa (26) susjednih vodonepropusnih ploča (14), pri čemu se svaka vodonepropusna ploča (14) sastoji od jedne vodonepropusne membrane od geosintetičkog materijala.
wherein ring is selected from Formula (v) to (vii): 
Spoj formule (Id): gdje je prsten izabran od formula (v) do (vii):
The dismantling system (5) according to any of claims 1 to 3, wherein the retaining means comprise at least one flange suitable for holding the casing (12) by means of driving said flange on the base of the casing (12). 
Sustav za rastavljanje (5) u skladu s patentnim zahtjevom 1, naznačen time što element za držanje (52) ima najmanje jednu prirubnicu, pogodan za držanje kućišta (12), pokretanjem navedene prirubnice na podnožje kućišta
is 5-12 membered heteroaryl, where said 5-12 membered heteroaryl is optionally substituted by 1 to 3 R32 groups; 
je 5-6-eročlani heteroaril, koji može biti supstituiran s 1 do 3 R32;
The thermoplastic film according to any preceding numbered embodiment, wherein the ratio of the width to the height of the fibre elements is in the range 3:1 to 1:3, preferably in the range 2:1 to 1:2, more preferably in the range 1.5:1 to 1:1.5. 
Termoplastična folija sukladno bilo kojem od prethodnih zahtjeva, pri čemu je omjer širine i visine elemenata vlakana 3:1 do 1:3, poželjno 2:1 do 1:2, najbolje 1.5:1 do 1:1.5.
or a pharmaceutically acceptable salt thereof, under suitable conditions to provide the compound of formula (II), or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof. 
N ili njegovom farmaceutski prihvatljivom solju, u uvjetima pogodnim za dobivanje spoja formule (1), ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese.
V. upon solidification. 
polimera nakon očvršćivanja.
C1-C6 alkyl optionally substituted with R4; 
-C6 alkil po izboru supstituiran s R4; benzil po izboru supstituiran s 1-3 R5;
Since the nozzle arrangement 1 has a very small flow across-section and is formed in particular as a capillary, a throttle effect is produced which is strong enough for the drawing-in of air by suction at this point to be reliably prevented, even without the non-return valve. 
Budući da naprava 1 s mlaznicom ima vrlo mali presjek protoka i ona je izrađena posebno u obliku kapilare, stvara se učinak gušenja, koji je dovoljan da se u tom trenutku pouzdano spriječi uvlačenja zraka, čak i bez nepovratnog ventila.
The combination of claim 10, wherein the combination is for treatment of diabetes mellitus type 2. 
Kombinacija u skladu s patentnim zahtjevom 10, naznačena time što je navedena kombinacija namijenjena upotrebi u liječenju dijabetesa melitusa tip 2.
5.4% by weight levodopa, 1.5% by weight carbidopa, 1% by weight ascorbic acid or Na ascorbate, and 12.3%, 13.5 or 14.8%, by weight arginine; or 7% by weight levodopa, 2% by weight carbidopa, 1 % by weight ascorbic acid or Na ascorbate, and 17.8% by weight arginine. 
(iv) 5.4% masenog udjela levodopa, 1,5% masenog udjela karbidopa, 1% masenog udjela askorbrinske kiseline ili natrijevog askorbata, i 12,3%, 13,5% ili 14,8% masenog udjela arginina; ili (v) 7% masenog udjela levodopa, 2% masenog udjela karbidopa, 1% masenog udjela askorbinske kiseline ili natrijevog askorbata, i 17,6% masenog udjela arginina.
isolating said protein composition having the intended glycosylation characteristics. In order to obtain a protein composition and particularly an antibody composition having improved properties, the host cell is selected to produce a protein/antibody composition having at least one of the following glycosylation characteristics: 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je namijenjen proizvodnji pripravka s molekulom proteina, po mogućnosti pripravka s molekulom protutijela, gdje se navedenu stanicu domaćin tako bira da proizvodi pripravak s proteinom koji ima najmanje jednu od sljedećih značajki glikoziliranja:
the side chain of the asparagine residue at amino acid position 298, according to EU numbering, is linked to a glycan though a B-glycosylamide linkage; 
bočni lanac asparaginskog ostatka na položaju aminokiseline 298, u skladu s EU označavanjem, vezan je na glikan preko B-glikozilamidne veze;
Composition according to one of the previous claims for use in the treatment of disorders of the gastro-intestinal tract, in particular of dyspeptic disorders, disorders which require the reduction of the gastric emptying time, in the treatment of Helicobacter pylori, in the irritable bowel syndrome (IBS), as well as gas, bloating, flatulence, and in the treatment of intestinal colics, especially in children and infants. 
Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je namijenjen upotrebi u liječenju poremećaja gastrointestinalnog sustava, osobito dispeptičnih poremećaja, poremećaja koji zahtijevaju skraćivanje vremena pražnjenja želuca, u liječenju bakterije Helicobacter pylori, kod sindroma iritabilnih crijeva (IBS), kao i plinova, nadutosti, vjetrova, te u liječenju crijevnih kolika, osobito kod djece i dojenčadi.
In certain embodiments, the first reactive group of the oligosaccharide may be reacted with the second reactive group of the aminooxy compound in the presence of a coupling agent, such as, e.g., EDC, and/or a catalyst, such as, e.g., NHS. 
K O O Postupak prema patentnom zahtjevu 10 ili 12, naznačen time što korak (c) obuhvaća reakciju prve reaktivne skupine oligosaharida s drugom reaktivnom skupinom aminooksi spoja u prisutnosti reagensa za spajanje i/ili katalizatora.
supplying the BOG generated in the cargo tank to at least one of the main engine and the sub engine as fuel through the compressor line in a laden condition in which an amount of the LNG stored in the cargo tank is larger than in a ballast condition. 
Sustav za obradu ukapljenog plina za plovilo, koji sadrži spremnik za teret (1;11), u kojem je spremljen ukapljeni zemni plin (LNG), te glavni motor (3) i pomoćni motor (200) koji koristi LNG spremljen u spremniku za teret kao gorivo, gdje sustav za obradu ukapljenog plina sadrži:
The container of claim 6, wherein the salt is the MH2 form of the L-lactic acid addition salt. 
Sol u skladu s patentnim zahtjevom 13, pri čemu je navedena sol dodatna sol L-mliječne kiseline.
The dosage form of any of claims 1 through 6, wherein said pharmaceutically acceptable polymer is a copolymer of N-vinyl pyrrolidone and vinyl acetate. 
Oblik doziranja u skladu s patentnim zahtjevom 1, naznačen time, da je navedeni farmaceutski prihvatljiv polimer kopolimer N-vinil pirolidona i vinil acetata.
The method of claim 45, wherein the sleep disorder is a sleep-wake transition disorder, insomnia, restless legs syndrome, jet-lag, disturbed sleep, or a sleep disorder secondary to neurological disorders. 
Spoj za uporabu prema zahtjevu 25, naznačen time da je poremećaj spavanja poremećaj prelaska 12 sna u budnost, nesanica, sindrom nemirnih nogu, jet-lag, poremećaj spavanja, ili sekundarni poremećaj spavanja u vezi s neurološkim poremećajima.
A compound of formula 1 according to any one of claims 1 to 8 for use as a medicament for the treatment of traumatic brain injury, abdominal aortic aneurism and Graft vs. 
Spoj formule 1 u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time, da se upotrebljava kao lijek za liječenje traumatske ozljede mozga, abdominalne aneurizme aorte i bolesti presadak protiv domaćina (GvHD - eng.
or a pharmaceutically acceptable salt thereof. A compound according to claim 1, of formula 1.a or a pharmaceutically acceptable salt thereof. 
Spoj u skladu sa patentnim zahtjevom 1 koje ima Formulu (II): ili njegov stereoizomer, tautomer, ili farmaceutski prihvatljiva sol, pri čemu:
a biologically active fragment of a G protein-coupled receptor of any one of (i) to (iii); and 
(iv) biološki aktivan fragment G protein-kupiranog receptora bilo kojeg (1) do (ili); te > m s
The combination for use of claim 7, wherein the diseases and conditions caused by elevated intraocular pressure in a human are selected from the group consisting of ocular hypertension, and primary open angle glaucoma. 
Kombinacija za uporabu u skladu s patentnim zahtjevom 7, pri čemu su bolesti i stanja uzrokovana povišenim intraokularnim tlakom u čovjeka odabrana iz grupe koja se sastoji od okularne hipertenzije i primarnog glaukoma otvorenog kuta.
As shown in FIG. 4 for illustration purposes only, two nozzles 12 A and 12 B are shown in parallel from end 16 of conduit 14 . 
Kako je prikazano na slici 4 samo u cilju ilustriranja, dvije mlaznice 12A i 12B pružaju se paralelno od kraja 16 cjevovoda 14.
The antibody or antigen-binding fragment thereof for use according to claim 12, wherein the synucleinopathic disease is Parkinson's disease. 
Protutijelo ili njegov fragment koji veže a-sinuklein u skladu s patentnim zahtjevom 3 za uporabu u skladu s patentnim zahtjevom 11, naznačen time da je sinukleinpatska bolest Parkinsonova bolest.
The use according to any of claims 7 to 9, wherein the cardiac condition is selected from the group consisting of cardiac arrhythmia, tachycardia, atrial arrhythmia, atrial tachyarrhythmia, atrial fibrillation, sustained atrial fibrillation, non-sustained atrial fibrillation, ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia, sustained ventricular tachycardia, non-sustained ventricular tachycardia, catecholaminergic polymorphic ventricular tachycardia (CPVT), heart failure, sudden cardiac death and exercise-induced sudden cardiac death. 
Uporaba prema bilo kojem od patentnih zahtjeva 9 ili 10, naznačena time što je srčano stanje izabrano iz grupe koju čine srčana aritmija, tahikardija, atrijalna aritmija, atrijalna tahiaritmija, atrijalna fibrilacija, dugotrajna atrijalna fibrilacija, kratkotrajna atrijalna fibrilacija, ventrikularna aritmija, ventrikularna fibrilacija, ventrikularna tahikardija, dugotrajna ventrikularna tahikardija, kratkotrajna ventrikularna tahikardija, kateholaminergička polimorfna ventrikularna tahikardija (CPVT), srčana insuficijencija, iznenadna srčana smrt i iznenadna srčana smrt izazvana pojačanom fizičkom aktivnošću.
compounds of the formula (VI) in which 
[C] spoj s formulom (VI)
A compound according to claim 1, 2 and 3 wherein said compound is compound No.1, compound No.8, compound No.11, compound No.9, compound No.33, compound No.34 compound No.7 or compound No. 25. 
Spoj prema patentnim zahtjevima 1, 2 i 3, naznačen time, da navedeni spoj je spoj br. 1, spoj br. 8, spoj br. 11, spoj br. 9, spoj br. 33, spoj br. 34, spoj br. 7 ili spoj br. 25.
The reaction was stirred at room temperature for 2.5 hours then was worked up by extracting with EtOAc and washing with water. 
Reakcijska smjesa je bila miješana na sobnoj temperaturi kroz 2.5 sata i tada je bila dorađena ekstrahiranjem s FtOAc i pranjem s vodom.
The invention provides a method for treating a patient, comprising administering a pharmaceutical composition of the invention to the patient. 
Izum daje metodu za liječenje pacijenta, koja se sastoji od davanja pacijentu farmaceutskog sastava iz izuma.
Stirring 24 hours at 0°. Then a solution of 2.2 g sulfuric acid in 22 ml water is added at RT, the slightly opal solution stirred for 15 minutes and then dropped to 500 ml water. 
Miješanje tijekom 24 sata na 0 "C. Zatim se doda otopina 2,2g sumporne kiseline u 22 ml vode na RT, lagano zamućena otopina se miješa tijekom 15 minuta i zatim se ukapa u 500 ml vode.
A pipe clamp as claimed in claim 1, wherein the divided closure comprises a snap connection which is provided with at least one protrusion and at least one closing cavity co-acting with the protrusion. 
Stezaljka za cijev prema Zahtjevu 1, gdje podijeljeni element za zatvaranje sadrži spojnicu kod koje se veza ostvaruje pritiskom a koja ima najmanje jedan istureni dio (37) i najmanje jednu zatvarajuću šupljinu (38) koja djeluje zajedno sa isturenim dijelom.
A door lock according to claim 7, characterised in that the second projection (38) is arranged to cooperate with the inner surface (30) of the front plate that is on the side edge of the bolt opening (16). 
Brava prema zahtjevu 7 naznačena time da se drugo izbočenje (38) koje treba djelovati sa unutrašnjom površinom (30) nalazi na postraničnom bridu otvora spone (16).
The plant according to the invention, in particular the rolling-mill 11, but already from continuous casting 10, is provided with a system for controlling the speed in a downstream cascade, where there is provided a device 14 for cutting the coils being wound on an end reel, after a final cooling system 13 . 
Postrojenje prema izumu, posebno valjaonica 11, ali već od kontinuiranog lijevanja 10, uključuje sustav nadzora brzine u nizvodnom nizu gdje se nalazi uređaj 14 za rezanje namotaja koji su namotani na zadnji kolut nakon zadnjeg sustava hlađenja 13.
The composition of claim 10, wherein the metabolic modulator is selected from the group consisting of polar aprotic solvents, DMSO, acetone, N,N-dimethylformanide, and acetonitrile. 
Postupak prema zahtjevu 10, naznačen time da je metabolički modulator odabran iz skupine koja sadrži polarna aprotička otapala, DMSO, aceton, N,N-dimetilformamid, i acetonitril.
Examples of selective alpha-1 adrenergic receptor agonists include oxymetazoline, phenylephrine, and methoxyamine. Examples of selective alpha-2 adrenergic receptor agonists include brimonidine, tetrahydrozoline, naphazoline, xylometazoline, epinephrine, and norepinephrine. 
Kompozicija topičkog gela prema zahtjevu 4, pri čemu je agonist alfa adrenergijskog receptora izabran iz grupe koja se sastoji od oksimetazolina, fenilefrina, metoksiamina, brimonidina, tetrahidrozolina, nafazolina, ksilometazolina, epinefrina, i norepinefrina.
placing the fish in first salt-controlled and temperature controlled solution having a salt concentration in the range from 0,1 to 10% and a temperature in the range from +1 to -3°C, where the salt concentration and set temperatures of the salt-controlled and temperature controlled solution brings the homogenous temperature of the fish to +2 to -1°C, and 
stavljanje ribe u prvu otopinu s kontroliranom količinom soli i s kontroliranom temperaturom, koja ima koncentraciju soli u rasponu od 0,1 do 10 % i temperaturu u rasponu od +1 do -3°C, pri čemu koncentracija soli i postavljene temperature u otopini s kontroliranom količinom soli i s kontroliranom temperaturom, dovodi homogenu temperaturu ribe na +2 do -1°C, i
about 300 mg. of netupitant as a free base on day one; 
oko 300 mg netupitantakao slobodna baza na dan jedan;
A compound for use according to claim 18 wherein the agent for treatment of obesity is a glucagon-like peptide receptor 1 agonist, peptide YY or analogue thereof, cannabinoid receptor 1 antagonist, lipase inhibitor, melanocortin receptor 4 agonist, or melanin concentrating hormone receptor 1 antagonist. 
Spoj za uporabu prema zahtjevu 18, naznačen time, da sredstvo za liječenje pretilosti je agonist receptora 1 peptida nalik na glukagon, peptid YY ili njegov analog, antagonist receptora 1 kanabinoida, inhibitor lipaze, agonist receptora 4 melanokortina ili antagonist receptora 1 hormonske koncentracije melanina.
The conjugate of claim 8, where said Taxol molecules are conjugated to said polypeptide as shown below: 
Konjugat prema zahtjevu 4, naznačen time da su navedene molekule Taxola konjugirane na navedeni polipeptid kako je prikazano ispod:
The method of claim 1, wherein the extracts of both species are obtained by extraction from roots or rhizomes with supercritical carbon dioxide. 
Kombinacija za upotrebu kao što je prijavljena u patentnom zahtjevu 1, naznačena time da su ekstrakti obaju vrsta dobiveni iz korijena ili rizoma ekstrakcijom superkritičnim ugljikovim dioksidom.
Users experienced fewer traumatic feelings and the quality of the diagnostic performance was considerably improved compared to the prior art, which improved subsequent conclusions in a laboratory considerably. 
Korisnice su doživjele nekoliko traumatskih osjećanja i kvaliteta dijagnostičkih postupaka se znatno poboljšala u usporedbi sa stanjem tehnike, što je znatno olakšalo kasnije postupke u laboratoriju.
The sidechain may be replaced, for example, with a compound of Formula 12 according to the generalized Scheme 9, shown in Figure 12. 
Bočni lanac može biti nadomješten, na primjer, s jednim spojem formule 12 u skladu s općom shemom 9, koja je prikazana na slici 12.
chain polypeptide of the YTE variant of 
Datum podnošenja europske prijave patenta:
A method of preparing D-psicose from D-glucose, wherein psicose-epimerase is isolated from Agrobacterium tumefaciens and expressed in a GRAS (generally accepted as safe) strain, wherein the GRAS strain is Corynebacterium glutamicum KCCM 11046, comprising the step of immobilizing a psicose-epimerase and a D-glucose isomerase onto carriers. The method of claim 7, wherein the expressed psicose-epimerase is contained in a culture of the GRAS strain or separated from the culture. 
Postupak pripremanja D-psikoze od D-glukoze, koji obuhvaća korak imobiliziranja psikoza-epimeraze i D-glukoza izomeraze na nosače, naznačen time da je psikoza-epimeraza dobivena od Agrobacterium tumefaciens, te je eksprimirana u GRAS soj (opće prihvaćena sigurna tvar), pri čemu GRAS soj je Corynebacterium glutamicum KCCM 11046, te pri čemu je psikoza-epimeraza sadržana u kultivatu GRAS soja, imobiliziranom na nosaču.
A method as in claim 22 wherein the composition is administered at least once a day for a period of at least one month. 
davanje navedenog pripravka u oko sisavca opetovano tijekom duljeg vremenskog razdoblja, pri čemu se poželjno pripravak primjenjuje najmanje jednom dnevno tijekom perioda od najmanje jednog mjeseca.
The method according to claim 2, wherein 1 to 10 consecutive nucleotides excluding an overhang nucleotide from a 3′ terminus of a sense strand of the siRNA are converted into DNA and 1 to 10 consecutive nucleotides from a 5′ terminus of an antisense strand of the siRNA are converted into DNA. 
siRNA u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time, da se 1 do 10 uzastopnih nukleotida s iznimkom izbočenog nukleotida iz 3' terminusa sens lanca siRNA pretvaraju u DNA i da se 1 do 10 uzastopnih nukleotida iz 5' terminusa antisens lanca siRNA pretvaraju u DNA.
The method of claim 4, wherein step (e) is performed with Purified Water (PW) except for the last repetition of step (e), which is performed with Water For Injection (WFI). 
9, Postupak sukladan bilo kojem od zahtjeva od 4 do 7, naznačen time, da se korak (d) provodi s pročišćenom vodom (PW) osim zadnjeg ponavljanja koraka (d) koje se provodi s vodom za injektiranje (WFI).
The method according to the proceedings claim 9, wherein the Area of Potential Influence of the planned placement of the new small cell is be determined according to one or more of the following steps: 
Postupak sukladno prethodnom zahtjevu 8, pri čemu Područje Potencijalnog Utjecaja planiranog smještanja male stanice može biti određeno sukladno jednom ili više sljedećih koraka:
coupling a compound of Formula la with a compound of Formula Ib in the presence of ethyl [(3-dimethylamino) propyl]carbodiimide-hydrochloride (EDCI-HCl), 2,6-lutidine, and a solvent suitable to provide conditions to form a reaction mixture containing the coupled amide product of Formula Ica; 
Formula la sa spojem Formule Ib Formula ib u prisutnosti etil [(3-dimetilamino) propil|karbodiimid-klorovodika (EDCI-HC]), 2,6-lutidina, 1 otapala koje je prikladno omogućiti uvjete za dobivanje reakcijske smjese koja će sadržavati spojeni amidni produkt Formule
The compound for use of claim 1, wherein the disease or disorder is genitourinary cancer. 
Spoj ili sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je karcinom jajnika.
The process of claim 13, wherein the concentration of H2SO4 is from about 25 g/L to about 35 g/L, and wherein the concentration of HF in the first mixture is from about greater than 0 g/L to about 100 g/L. 
8. Postupak u skladu s patentnim zahtjevom 7, naznačen time što se koncentracija H,SO, kreće od 25 g/I do 35 g/l, a koncentracija HF se kreće od 0 g/l do 100 g/l.
4,379,785), glipizide, gliclazide or chlorpropamide, other known sulfonylureas or other antihyperglycemic agents which act on the ATP-dependent channel of the beta-cells, with glyburide and glipizide being preferred, which may be administered in the same or in separate oral dosage forms. 
4,379,785), glipizid, gliklazid ili klorpropamid, druge poznate sulfoniluree ili drugi antihiperglikemijski agensi koji djeluju na ATP-ovisne kanale beta stanica, pri čemu su poželjni gliburid i glipizid, koji se mogu unositi u istim ili odvojenim oblicima oralnih doza.
The base station apparatus according to one of claims 1 to 2, wherein said allocating unit is configured to allocate, in the second allocation, one or more of the RBGs to the mobile station apparatus. 
Integrirani krug sukladno zahtjevu 1 ili 2, naznačen time da je u drugoj dodjeli, dodijeljen jedan ili više RBG-a uređaju mobilnoj stanici.
Therefore polymorphs of a compound usually differ with regard to their dissolution characteristics and their bulk properties. 
Prema tome, polimorfi spoja obično se razlikuju s obzirom na njihove karakteristike otapanja i njihova ukupna svojstva.
A mixture of anhydrous pyridine (52 mL), benzoyl chloride (51.5 mL, 0.444 mmol) and anhydrous dichloromethane (125 mL) was cooled to −10° C. Finely powdered fructose (20 g, 0.111 mmol) was added portion wise and the reaction mixture was stirred at −10° C. for 18 hours. 
Smjesa bezvodnog piridina (52 mL), benzoil-klorida (51,5 mL, 0,444 mmol) i bezvodnog diklorometana (125 mL) ohlađena je na -10?C. Fino smrvljena fruktoza (20 g, 0,111 mmol) dodana je dio po dio i reakcijska smjesa miješana je
wherein PLG is the protecting-leaving group as set forth in claim 1, X is Cl or Br, Y is NO2 or NH2, and Z is hydrogen, hydroxyethyl or the group convertible to hydroxyethyl as set forth in claim 1. 
x gdje je PLG zaštitno-izlazna skupina kao što je izneseno u zahtjevu 1, X je Clili Br, Y je NO, ili NH., i Zje vodik, hidroksietil ili skupina koja se može pretvarati u hidroksietil, kao što je izneseno u zahtjevu 1.
A compound or salt according to claim 1 in which X is O and R3 is C1-C3 straight or branched alkyl optionally substituted by from 1 to 3 halogen atoms. 
Spoj ili sol u skladu s patentnim zahtjevom 1, naznačen time što X je O, a R3 je C1-C3 nerazgranati ili razgranati alkil, izborno supstituiran s 1 do 3 atoma halogena.